REGORAFENIB DOPO TACE PER CARCINOMA EPATICO NON RESECABILE: UNO STUDIO DI REAL-WORLD EVIDENCE
Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study Yue Han et al. Abstract Background The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC). This study aimed to explore the benefits and tolerability of TACE combined with…

